Blockchain Registration Transaction Record

Oragenics to License Sigyn's CardioDialysis for Brain Injury

Oragenics (OGEN) and Sigyn Therapeutics sign letter of intent for exclusive license of CardioDialysis blood purification technology for traumatic brain injury and neurodegenerative diseases, complementing ONP-002 neurosteroid.

This news matters because traumatic brain injury (TBI) is a leading cause of disability and death worldwide, yet there are no FDA-approved drugs specifically for TBI. The dual-modality approach combining blood purification (CardioDialysis) with an intranasal neurosteroid (ONP-002) could address inflammation both inside and outside the brain, potentially improving outcomes for millions of patients. If successful, this strategy could also be applied to chronic neurodegenerative diseases like Alzheimer's and Parkinson's, offering new hope for conditions that currently have limited treatment options. The partnership also signals increased investment in innovative therapies for neurological disorders, a field with significant unmet medical need.